Session Details

F041 Rheumatology for the Dermatologist: Evaluating the Rheumatology Patient in the Dermatology Clinic

Sat, Mar 20, 3:30 PM - 5:30 PM
2 CME Available Forum

DESCRIPTION

The “Rheumatology for the Dermatologist” session at AAD 2027 will offer dermatologists cutting-edge updates on autoimmune and inflammatory skin diseases. Rapid-fire talks by leading experts will explore targeted and cell-based therapies in dermatomyositis, practical management of systemic sclerosis, evolving CLE and SLE treatments, emerging cellular and fibrosis therapies, autoimmune toxicity in immuno-oncology, modern serologic interpretation, and inflammatory arthritis differentials. Designed for dermatologists, the session highlights diagnostic precision, novel therapeutics, and multidisciplinary care at the dermatology–rheumatology interface.

LEARNING OBJECTIVES

1.

Discuss emerging therapies for cutaneous lupus erythematosus (CLE), including novel biologics, small molecules, and precision approaches targeting immune and molecular pathways driving disease.

2.

Interpret serologic and biomarker data to improve diagnosis, disease stratification, and management across autoimmune and connective tissue skin diseases.

3.

Apply multidisciplinary strategies for complex autoimmune dermatoses, integrating advances in systemic sclerosis, dermatomyositis, arthritis, and immune checkpoint–related toxicities.

SCHEDULE

3:30 PM

Dermatomyositis Therapeutics: Flexing New Treatment Options

Scott Elman, MD, FAAD

3:45 PM

Systemic Sclerosis in a Flash: What the Dermatologist Needs to Know

Rebecca Gaffney, MD, FAAD

3:55 PM

Cutaneous Lupus: Current and Emerging Therapies

Joseph Merola, MD, MSc, FAAD

4:10 PM

SLE Screening and Monitoring for the Dermatologist

4:20 PM

Is It Inflammatory Arthritis? Peripheral and Axial Screening for the Dermatologist

Alice B. Gottlieb, MD, PhD, FAAD

4:30 PM

Rapid-Fire Serologies: Making Sense of Autoimmune Testing

Jeffrey Smith, PhD, MD, FAAD

4:30 PM

Sarcoidosis: Current and Emerging Therapies

Sotonye Imadojemu, MD, FAAD

4:40 PM

Morphea: Emerging Treatment Considerations

5:00 PM

Cutaneous Autoimmune Disease Considerations in Cancer Immunotherapy

Jennifer N. Choi, MD, FAAD

5:15 PM

Panel Discussion and Audience Q&A

DIRECTOR

Joseph Merola, MD, MSc, FAAD

Joseph Merola, MD, MSc, FAAD

UT Southwestern Medical Center

SPEAKERS

Jennifer N. Choi, MD, FAAD

Jennifer N. Choi, MD, FAAD

Scott Elman, MD, FAAD

Scott Elman, MD, FAAD

University of Miami

Rebecca Gaffney, MD, FAAD

Rebecca Gaffney, MD, FAAD

Alice B. Gottlieb, MD, PhD, FAAD

Alice B. Gottlieb, MD, PhD, FAAD

Ut Southwestern Medical Center, Dallas, TX

Sotonye Imadojemu, MD, FAAD

Sotonye Imadojemu, MD, FAAD

Jeffrey Smith, PhD, MD, FAAD

Jeffrey Smith, PhD, MD, FAAD

DISCLOSURES

Jennifer N. Choi, MD, FAAD

CeraVe/Valeante – Independent Contractor(Fees); Janssen Global Services, LLC – Advisory Board(Fees); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Fees); OnQuality Pharmaceuticals, Ltd. – Advisory Board(Fees); PraHealth Sciences – Advisory Board(Fees); Pyxis Oncology – Advisory Board(Fees); Regeneron Pharmaceuticals, Inc. – Data Safety Monitoring Board(Fees);

Scott Elman, MD, FAAD

Biogen – Consultant(Fees); Blueprint Medicines – Advisory Board(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);

Rebecca Gaffney, MD, FAAD

No financial relationships exist with ineligible companies.

Alice B. Gottlieb, MD, PhD, FAAD

AstraZeneca – Consultant (1099 relationship)(Honoraria); Biogen – Consultant (1099 relationship)(Honoraria); BMS – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(Honoraria); Galderma – Consultant (1099 relationship)(Honoraria); janssen – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Consultant(Honoraria); Novartis – Advisory Board(Honoraria), Consultant(Honoraria); Oruka Therapeutics – Advisory Board(Honoraria); sanofi-aventis – Consultant (1099 relationship)(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); ucb – Advisory Board(Honoraria);

Sotonye Imadojemu, MD, FAAD

No financial relationships exist with ineligible companies.

Joseph Merola, MD, MSc, FAAD

AbbVie – Consultant(Honoraria); Amgen – Advisory Board(Honoraria); AstraZeneca – Consultant (1099 relationship)(Fees); Biogen – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol-Myers Squibb – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Consultant(Honoraria); Galderma – Consultant (1099 relationship)(Fees); Janssen Pharmaceuticals, Inc – Consultant(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Novartis – Consultant(Honoraria); Pfizer Inc. – Investigator(Fees); Sanofi/Regeneron – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria);

Jeffrey Smith, PhD, MD, FAAD

Biogen – Investigator(Grants/Research Funding); Formation Bio – Consultant (1099 relationship)(Fees);